Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases

Chang, Connie Y.; Gill, Corey M.; Simeone, F. A.; Taneja, Atul K.; Huang, Ambrose J.; Torriani, Martin; Bredella, Miriam A.

doi:10.1177/0284185114564438

Cited by 46 publications

(52 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone metastases are typically characterized as 'osteolytic', 'osseous' or 'mixed', according to the radiographic and/or pathologic major appearance of the lesions 26 . Compared with bone scan, 18 F-FDG PET/CT showed higher sensitivity for detecting osteolytic and mixed bone metastases 6 , 27 . Our results demonstrated that 18 F-Alfatide II PET/CT had similar detection efficiency as 18 F-FDG PET/CT for the detection of osteolytic and mixed bone metastases.…”

Section: Discussionmentioning

confidence: 98%

“…First, our study lacks histologic verification for the imaging findings because it is not ethical to perform biopsy on patients diagnosed with bone metastasis. Instead, we used a combination of follow-up imaging and clinical management data to verify PET/CT findings, which has commonly been used in previous clinical studies 6 . Second, no comparison with bone scans using either 99m Tc-MDP or 18 F-NaF 35 was made.…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, the application of FDG PET/CT to detect skeletal metastatic disease has been intensively investigated. Most reports suggest that FDG PET/CT is superior to bone scan in the detection of skeletal metastatic disease 6 , 7 . Similar to the primary lesion, visualization of bone metastasis by FDG PET/CT is also based on the increased metabolic activity rather than anatomical alterations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases

Mi¹,

Yu²,

Pan³

et al. 2015

Theranostics

View full text Add to dashboard Cite

This pilot prospective evaluation study is to verify the efficiency of 18F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to 18F-FDG PET. Thirty recruited patients underwent 18F-FDG and 18F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of 18F-Alfatide II and 18F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. 18F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than 18F-FDG PET (77%). Especially, 18F-Alfatide II PET showed superiority to 18F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, 18F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of 18F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of 18F-FDG PET/CT. This pilot clinical study warrants the further application of 18F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases

Mi¹,

Yu²,

Pan³

et al. 2015

Theranostics

View full text Add to dashboard Cite

show abstract

“…Some controversies emerged when comparing 18 F-FDG PET/CT and 99m Technetium-methylene diphosphonate-planar bone scintigraphy ( 99m Tc-MDP-BS) for the detection of BM from different cancer types [35]. In DTC with BM, the accuracy of 18 F-FDG PET/CT is significantly higher than that of 99m Tc-MDP-BS [28,36].…”

Section: Diagnostic Rolementioning

confidence: 99%

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Nervo

Ragni

Retta

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

Bone represents the second most common site of distant metastases in differentiated thyroid cancer (DTC). The clinical course of DTC patients with bone metastases (BM) is quite heterogeneous, but generally associated with low survival rates. Skeletal-related events might be a serious complication of BM, resulting in high morbidity and impaired quality of life. To achieve disease control and symptoms relief, multimodal treatment is generally required: radioiodine therapy, local procedures-including surgery, radiotherapy and percutaneous techniques-and systemic therapies, such as kinase inhibitors and antiresorptive drugs. The management of DTC with BM is challenging: a careful evaluation and a personalized approach are essential to improve patients' outcomes. To date, prospective studies focusing on the main clinical aspects of DTC with BM are scarce; available analyses mainly include cohorts assembled over multiple decades, small samples sizes and data about BM not always separated from those regarding other distant metastases. The aim of this review is to summarize the most recent evidences and the unsolved questions regarding BM in DTC, analyzing several key issues: pathophysiology, prognostic factors, role of anatomic and functional imaging, and clinical management.

show abstract

“…37 ). Some authors observed poorer detection of metastases particularly in the pelvis, spine and sacrum with the planar scintigraphy 38 . The greatest benefit of SPECT/CT is reported, however, for these localizations 24 .…”

Section: Comparison With Hybrid Systems Using Petmentioning

confidence: 99%

SPECT/CT imaging in breast cancer - current status and challenges

Simanek

Koranda²

2016

BIOMED PAP

View full text Add to dashboard Cite

Background. The increasing incidence of breast cancer worldwide raises the importance of improving imaging techniques for disease stratification after early lesion detection. SPECT/CT imaging is now widely available but its diagnostic potential is not fully utilized for more specific purposes including breast cancer patient stratification. Methods and Results. A Pubmed search for both original and review articles related to the value of SPECT/CT in breast cancer patients and comparison to other diagnostic methods. 62 articles were found using the key words SPECT/CT, Fusion Image and Breast Cancer. Development of a new generation of SPECT/CT systems and their introduction into practice has changed the old diagnostic algorithm. The increasing importance of SPECT/CT in the detection of bone metastases is confirmed. The diagnostic accuracy of new SPECT/CT instruments in the diagnostics of bone metastases is nearly comparable to PET/CT scans. SPECT/CT is more widely available and costs less than PET. It is able not only to identify a sentinel lymph nodes in atypical localizations but also to detect sentinel lymph nodes non visualized on previous planar scans. SPECT/CT offers precise anatomic localization of sentinel lymph nodes, thereby facilitating surgery. Knowledge of precise sentinel lymph node localization can also be applied in radiotherapy. Conclusions. The role of hybrid SPECT/CT imaging in breast cancer patients is changing. It is a powerful modality for skeletal and nodal staging in breast cancer patients with important impact on therapy.

show abstract

Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases

Abstract: FDG PET/CT is an accurate technique for detection of skeletal metastases, and is superior to bone scan, especially in the spine and pelvis.

Cited by 46 publications

References 30 publications

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

SPECT/CT imaging in breast cancer - current status and challenges

Contact Info

Product

Resources

About

Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases

Abstract: FDG PET/CT is an accurate technique for detection of skeletal metastases, and is superior to bone scan, especially in the spine and pelvis.

Cited by 46 publications

References 30 publications

Pilot Prospective Evaluation of 18F-Alfatide II for Detection of Skeletal Metastases

Pilot Prospective Evaluation of 18F-Alfatide II for Detection of Skeletal Metastases

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

SPECT/CT imaging in breast cancer - current status and challenges

Contact Info

Product

Resources

About

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases

Pilot Prospective Evaluation of ¹⁸F-Alfatide II for Detection of Skeletal Metastases